Turning 65 today means something very different than it did 30 years ago. Today’s seniors experienced the antibiotic revolution, the cardiac care breakthrough, and the dawn of cancer therapies that weren’t available during their parents’ time. Those breakthroughs were made possible by decades of investment in medical research and an innovation ecosystem that turns scientific discovery into lifesaving medicines. That system has made the United States the world’s leader in medical innovation, but that leadership is no longer guaranteed.
Emerging global competitors, particularly China, are investing aggressively in biomedical innovation and rapidly accelerating the pace of drug development. China now moves from molecule discovery to human clinical trials almost 70% faster than any other country, underscoring the speed at which the global innovation race is evolving. If the U.S. continues its current path, it risks ceding its leadership in medical innovation and denying the next generation of seniors the same lifesaving advances today’s older Americans have benefited from.
America doesn’t risk losing its leadership because our scientists are less capable than China’s. We risk losing it because our own regulatory system is making it harder to bring new discoveries to patients. A new report identifies a specific bottleneck threatening America’s leadership: unnecessary delays in the Food and Drug Administration approval process. While we can all agree that patient safety must remain the priority, much of the lengthy FDA approval timeline is driven not by safety reviews but by prolonged effectiveness evaluations. As a result, therapies that have already demonstrated they are safe can remain unavailable to patients for years while additional efficacy data is collected.
These unnecessary delays keep promising treatments out of the hands of patients far longer than they should, weakening health outcomes and America’s competitive edge at a time when global rivals are racing to lead the next generation of medical innovation. Operation Warp Speed demonstrated that it is possible to accelerate drug development and review while maintaining robust safety standards. Despite those lessons, the FDA has largely returned to a slower regulatory framework, delaying patient access to lifesaving therapies and allowing other nations to gain ground in biomedical innovation.
And the cost is staggering. Accelerating the FDA’s drug review process by just one year could generate as much as $10.2 trillion in economic value. But those gains represent far more than increased productivity or economic output. For older people facing a cancer diagnosis, a decadelong approval process can mean the difference between surviving from a lifesaving treatment and never having the opportunity to receive it. Between 2030 and 2064, an estimated 30.7 million Americans, many of them seniors, will die from cancer. Eliminating cancer mortality would generate $186 trillion in economic benefits over the next 35 years while preventing those 30.7 million deaths. Every unnecessary delay represents lost time that many people do not have.
As China rapidly expands its investments in biotechnology, the U.S. cannot afford to let outdated regulatory processes become a competitive disadvantage. The nation that discovers the next generation of cancer therapies will save lives and shape the future of global biomedical leadership and economic growth. Delays in bringing new therapies to market threaten America’s long-standing leadership in medical innovation, risking both its competitive edge and its ability to ensure that seniors are the first to benefit from innovation.
KENNEDY’S HHS IS SACRIFICING CANCER CURES FOR TRIAL BAR PROFITS
Modernizing the FDA does not mean lowering safety standards. It means bringing the agency’s effectiveness review process into the 21st century by embracing the tools and scientific capabilities that already exist. Faster clinical trial designs, artificial intelligence, and modern regulatory approaches can preserve rigorous safety oversight and keep the U.S. agency as the gold standard while reducing unnecessary delays that keep lifesaving therapies out of patients’ hands.
America’s seniors have spent their lives benefiting from their country’s leadership in medical innovation. They should not have to watch that leadership slip away because Washington failed to modernize the systems designed to deliver it. The innovation race with China is already underway, and America’s seniors cannot afford to lose it to Washington’s bureaucratic drag.
Saulius “Saul” Anuzis is the president of the 60 Plus Association, known as the American Association of Senior Citizens.